Post-docetaxel treatments for metastatic castrationresistant prostate cancer: A spanish single center experience

• Autores: Laura Delgado Téllez, Amaia Egües Lugea, Carmen Perezagua Marín, Mª Carmen Herrero Domínguez-Berrueta, María Angeles Campos Fernández de Sevilla, Federico Tutau Gómez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 3, 2016, págs. 178-181
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • New treatments have been available for metastatic Castration-Resistant Prostate Cancer (mCRPC).

    Purpose: To describe effectiveness and safety of different new treatments in mCRPC patients treated with docetaxel.

    Method: A retrospective observational study in 10 mCRPC patients. The Progression-Free Survival (PFS), Overall Survival (OS) and safety of abiraterone and cabazitaxel has been measured.

    Results: Abiraterone has been well tolerated with greater PFS and PSA response but less OS than pivotal study. Cabazitaxel had better PFS but less OS than pivotal study with a high incidence of asthenia.

    Conclusions: Abiraterone has been the second line most used followed by cabazitaxel, but not all patients have been candidates for three lines. A better knowledge of the sequencing current therapies will allow to increase effectiveness in these patients